The US Food and Drug Administration (FDA) has approved IntelGenxs’ anti-depressant CPI-300 to treat patients with major depressive disorder.

CPI-300 is a single dose 450mg formulation of bupropion hydrochloride.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

IntelGenx president and CEO Horst Zerbe said that physicians would embrace CPI-300 as a safe alternative for patients requiring high-dose anti-depressant therapy.

”So we now turn our focus towards the commercialisation of CPI-300, with the objective of a product launch with a partner by the second quarter of 2012," Zerbe added.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact